NCT03966742View on ClinicalTrials.gov

Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
DesmoidDesmoid Fibromatosis of SkinDesmoid Neoplasm of Chest WallDesmoid Tumor Caused by Somatic MutationAggressive FibromatosesFibromatosis DesmoidDesmoid Fibromatosis
Interventions
PROCEDURE

Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis

"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."

Trial Locations (1)

Unknown

Rabin Medical Center, Petah Tikva

All Listed Sponsors
lead

Rabin Medical Center

OTHER

NCT03966742 - Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis | Biotech Hunter | Biotech Hunter